HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics (NASDAQ:LVTX) and maintains a $6 price target.
June 28, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on LAVA Therapeutics (NASDAQ:LVTX) and maintains a $6 price target.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100